genetic testing

The investment bank gave shares of the Temple City, California-based genetic testing company a buy rating and a $20 price target.

The deal includes integrating an online ordering process for Ambry's genetic tests into Volpara's Aspen Breast software for medical practice management.

The San Francisco-based firm reported $64.2 million in revenues, up from $40.6 million a year ago and beating the average Wall Street estimate of $59.4 million.

Illumina had sought to exclude the Harmony test from the US Market, while Ariosa had sought to overturn the jury verdict with a post-trial maneuver.

Blueprint Genetics, recently acquired by Quest Diagnostics in January, will base the 600-gene panel on its whole-exome sequencing capability.

The companies will join their respective technologies to provide pharmacogenomic information for patients undergoing genetic testing.

Invitae will provide genetic testing for 109 genes associated with the conditions, while BioMarin will provide financial support for the program.

The platform matches a patient's medical history and other data with national guidelines to recommended medically actionable genetic tests.